Community Webinar with MavriX Bio

MavriX Bio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MVX-220, an investigational adeno-associated virus (AAV) gene therapy for the treatment of Angelman syndrome.  

The Phase 1/2 Clinical Trial (ASCEND-AS) to study of the safety and efficacy of MVX-220 is now listed on ClinicalTrials.gov: NCT07181837 

Community webinar

Co-hosted by FAST and ASF Join for information about the upcoming trial of MVX-220. MavriX Bio will provide a summary of the trial design, requirements, and enrollment criteria.